Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines…
Amneal co-CEO Chirag Patel said the industry is entering 'the golden era for biosimilars,' as he explained the motivation for the $1.1 billion acquisition of…
Health Canada validated and accepted the Market Authorization Application (MAA) for ADL-018, a proposed biosimilar to XOLAIR (omalizumab). 'The acceptance of…
Source summaries from our enrichment pipeline; follow links for originals.
All 8 sources with sentiment breakdown →
Amneal (AMRX) entered a definitive agreement to acquire 100% of Kashiv BioSciences for $375M cash plus $375M equity at closing and up to $350M in regulatory-milestone and commercial-royalty payments, plus operating funding through closing. Establishes a fully integrated global biosimilars platform.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC (this deal) | 2026 | $1.1B | — |
| Amneal Pharmaceuticals Inc. / Kashiv BioSciences LLC | 2024 | — | — |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
| Kohlberg Kravis Roberts & Co. / PRA International (Genstar Capital) | 2013 | $1.3B | 91 |
| Stryker Corporation / MAKO Surgical Corp. | 2013 | $1.6B | 91 |
| Quintiles Transnational Holdings Inc. / IMS Health Holdings, Inc. | 2016 | $17.6B | 91 |
| DPx Holdings B.V. (JLL Partners 51% / Royal DSM 49%) / Patheon Inc. + DSM Pharmaceutical Products | 2013 | $2.6B | 90 |
← Browse all deals · How we score deals
More: 2026 deals · Other deals